Loss of miR-101-3p Promotes Transmigration of Metastatic Breast Cancer Cells through the Brain Endothelium by Inducing COX-2/MMP1 Signaling.
blood–brain barrier
brain metastasis
breast cancer
micro-RNA
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
07 Jul 2020
07 Jul 2020
Historique:
received:
01
07
2020
revised:
03
07
2020
accepted:
06
07
2020
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
11
7
2020
Statut:
epublish
Résumé
Brain metastases represent one of the incurable end stages in breast cancer (BC). Developing effective or preventive treatments is hampered by a lack of knowledge on the molecular mechanisms driving brain metastasis. Transmigration of BC cells through the brain endothelium is a key event in the pathogenesis of brain metastasis. In this study, we identified miR-101-3p as a critical micro-RNA able to reduce transmigration of BC cells through the brain endothelium. Our results revealed that miR-101-3p expression is downregulated in brain metastatic BC cells compared to less invasive variants, and varies inversely compared to the brain metastatic propensity of BC cells. Using a loss-and-gain of function approach, we found that miR-101-3p downregulation increased transmigration of BC cells through the brain endothelium in vitro by inducing COX-2 expression in cancer cells, whereas ectopic restoration of miR-101-3p exerted a metastasis-reducing effect. In regulatory experiments, we found that miR-101-3p mediated its effect by modulating COX-2-MMP1 signaling capable of degrading the inter-endothelial junctions (claudin-5 and VE-cadherin), key components of the brain endothelium. These findings suggest that miR-101-3p plays a critical role in the transmigration of breast cancer cells through the brain endothelium by modulating the COX-2-MMP1 signaling and thus may serve as a therapeutic target that can be exploited to prevent or suppress brain metastasis in human breast cancer.
Identifiants
pubmed: 32645833
pii: ph13070144
doi: 10.3390/ph13070144
pmc: PMC7407639
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Terry Fox Foundation
ID : I1032
Organisme : The University of Sharjah
ID : The University of Sharjah competitive grant (No. 180111030)
Références
Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
FEBS J. 2012 Nov;279(22):4201-12
pubmed: 23013439
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):132-147
pubmed: 28341420
Mol Med Rep. 2014 Mar;9(3):779-85
pubmed: 24366267
Oncogene. 2012 May 17;31(20):2499-511
pubmed: 21963843
Mol Cell Biol. 2004 Oct;24(19):8408-17
pubmed: 15367662
Anticancer Res. 2011 Dec;31(12):4307-13
pubmed: 22199296
Drug Des Devel Ther. 2015 Feb 18;9:1103-75
pubmed: 25733820
J Neurosci. 2013 Apr 3;33(14):5992-6000
pubmed: 23554480
PLoS One. 2015 Nov 10;10(11):e0140642
pubmed: 26556718
Cancer Cell Int. 2012 Dec 19;12(1):53
pubmed: 23249419
Cancer Prev Res (Phila). 2011 Jul;4(7):1073-83
pubmed: 21430074
Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):245-58
pubmed: 27365375
Methods Mol Biol. 2011;762:333-45
pubmed: 21717368
Oncogene. 2015 Sep 10;34(37):4890-900
pubmed: 25659578
Nat Biotechnol. 2013 Jul;31(7):577
pubmed: 23839128
Med Sci Monit. 2017 Apr 18;23:1857-1871
pubmed: 28416776
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15144-9
pubmed: 17848513
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Cell Physiol Biochem. 2014;34(2):413-22
pubmed: 25059472
Cancer Med. 2018 Aug;7(8):3820-3833
pubmed: 29992751
Neuro Oncol. 2018 Oct 9;20(11):1439-1449
pubmed: 29566179
Front Biosci (Schol Ed). 2016 Jan 01;8:187-202
pubmed: 26709907
Int J Mol Sci. 2014 Jun 11;15(6):10508-26
pubmed: 24921708
Nat Rev Clin Oncol. 2011 Jun;8(6):344-56
pubmed: 21487419
Front Biosci (Elite Ed). 2016 Jan 01;8:245-63
pubmed: 26709660
Exp Cell Res. 2009 May 1;315(8):1439-47
pubmed: 19133256
Nat Rev Clin Oncol. 2019 Mar;16(3):185-204
pubmed: 30514977
Int J Mol Sci. 2016 Dec 09;17(12):
pubmed: 27941681
Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412
pubmed: 25561720
J Biol Chem. 2015 Apr 10;290(15):9842-54
pubmed: 25691572
Trends Cancer. 2018 Mar;4(3):176-196
pubmed: 29506669
Nature. 2011 Dec 14;481(7380):190-4
pubmed: 22170610
Cancer Lett. 2016 Dec 1;383(1):18-27
pubmed: 27693460
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Cancer Genomics Proteomics. 2015 Jul-Aug;12(4):167-77
pubmed: 26136217
Nat Biotechnol. 2008 Apr;26(4):462-9
pubmed: 18362881
Oncotarget. 2015 Oct 13;6(31):30818-30
pubmed: 26360780
Cancer Cell. 2015 Feb 9;27(2):163-75
pubmed: 25670078
Curr Neuropharmacol. 2018;16(9):1375-1384
pubmed: 29473514
Breast. 2014 Oct;23(5):623-8
pubmed: 24993072
Cancer Res. 2011 Feb 1;71(3):645-54
pubmed: 21266359
Nature. 2009 Jun 18;459(7249):1005-9
pubmed: 19421193
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
J Hepatol. 2015 Feb;62(2):448-57
pubmed: 25308172
Am J Transl Res. 2017 May 15;9(5):2088-2105
pubmed: 28559963
Nature. 2008 Jan 10;451(7175):147-52
pubmed: 18185580
PLoS One. 2012;7(10):e46173
pubmed: 23071542
Nat Commun. 2015 Apr 01;6:6716
pubmed: 25828099
Int J Mol Sci. 2013 Jan 11;14(1):1383-411
pubmed: 23344048
J Bone Miner Res. 2001 Aug;16(8):1486-95
pubmed: 11499871
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
Oncol Lett. 2016 Oct;12(4):2538-2544
pubmed: 27698824